Stifel analyst Stephen Willey reiterated a Buy rating and $44.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).The analyst commented, "Lighter-than-anticipated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE